Cleveland BioLabs, Inc. (NASDAQ:CBLI)

CAPS Rating: 3 out of 5

The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.

Recs

2
Player Avatar NetscribeServcs (20.91) Submitted: 3/21/2007 7:51:49 AM : Underperform Start Price: $8.90 CBLI Score: +142.23

Cleveland Biolabs (CBL) is a biotechnology research and development company, which develops drugs offering protection from radiation and cancer. CBL is engaged in the development of small molecule drugs and biologics focusing on two therapeutic directions, which includes development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (protectans), and development of anti-cancer drugs for regulating cell death (curaxins).
Financially company has been running in losses from past three-four years. For the nine months ended in 2006, company’s revenues increased 93% to $1.5 million predominantly driven by increase in government grants. But it had a net loss totaled of $4.3 million, which was owing to an increase in selling, general and administrative expenses. Also due to creating and improving the infrastructure of the company and higher research & development expenses incurred for internal projects.
CBL intends to respond to a Request for Proposal (RFP) recently issued by the Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures to treat gastrointestinal effects of acute radiation syndrome. More recently company completed a $30 million private placement. This will provide them with two years of working capital and enable them to fulfill the requirements of the DoD's RFP as well as move forward with the development of radiation protection, cancer treatment and stem cell proliferation. But the above would gain only in the long run.
Looking at all the above factors and consequently due to increasing expenses in research & development every year coupled with deteriorating financials, the scrip is expected to enter a bearish phase.

Featured Broker Partners


Advertisement